Pyxis Oncology (PYXS) Capital Leases (2024 - 2025)
Pyxis Oncology's (PYXS) quarterly Capital Leases came in at $23000.0 in Q4 2025, down 77.0% year-on-year from $100000.0 in Q4 2024, and down 46.51% on a QoQ basis from $43000.0 in Q3 2025.
Pyxis Oncology (PYXS) Capital Leases (2024 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 2 years of Capital Leases data on file, last reported at $23000.0 in Q4 2025.
- On a quarterly basis, Capital Leases fell 77.0% year-over-year to $23000.0 in Q4 2025; TTM through Dec 2025 was $23000.0, a 77.0% decrease from a year earlier, with the FY2025 full-year figure at $23000.0, down 77.0% from the prior year.
- Capital Leases for Q4 2025 stood at $23000.0, down from $43000.0 in the prior quarter.
- Over the last five years, Capital Leases for PYXS reached as high as $135000.0 in Q2 2024 and fell as low as $23000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Pyxis Oncology | 166.54 Mn | 99.69 Mn | 8.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23,000.00 |
| Sep 30, 2025 | 43,000.00 |
| Jun 30, 2025 | 62,000.00 |
| Mar 31, 2025 | 80,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 117,000.00 |
| Jun 30, 2024 | 135,000.00 |